We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Smart Nanoparticles Deliver Selective Heating to Kill Tumors

By LabMedica International staff writers
Posted on 28 Jul 2016
Cancer researchers have demonstrated a novel type of "smart" nanoparticle that can destroy a tumor through selective heating while causing minimal damage to surrounding normal tissues.

Investigators at University Health Network (Toronto, Canada) described the use of PEARLs (photo-thermal enhancing auto-regulating liposomes) in a proof-of-concept paper that was published in the July 14, 2016, online edition of the journal Angewandte Chemie.

Photothermal therapy (PTT) is enhanced by the use of nanoparticles with a large optical absorption at the treatment wavelength. More...
However, this comes at the cost of higher light attenuation that results in reduced depth of heating as well as larger thermal gradients, leading to potential over- and under-treatment in the target tissue. These limitations can be overcome by using PEARLs, which are based on thermochromic J-aggregate forming dye–lipid conjugates that reversibly alter their absorption above a predefined lipid phase-transition temperature.

The investigators showed - in nanoparticle solutions and in gel phantoms containing the nanoparticles - that under irradiation by near-infrared light, deeper layers of the target tissue reverted to the intrinsic optical absorption, halting the temperature rise and enabling greater light penetration and heat generation at depth.

Senior author Dr. Gang Zheng, professor of medical biophysics at the University Health Network, said, "Our smart nanoparticle is super cool. It can absorb light, generate heat, and ablate the tumor. It is a thermal sensor and once it reaches the desired ablation temperature of 55 degrees Celsius, it becomes invisible allowing the light to move deeper into more areas of tumor and repeat the treatment process. The result is a promising new way to heat and ablate larger volumes of tumor with minimal damage to surrounding tissues in a controlled and precise way. The next step is to conduct pre-clinical studies to test the concept further."

Related Links:
University Health Network



Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.